Versatility of liquid crystalline nanoparticles in inflammatory lung diseases
Nanomedicine (Lond)
.
2021 Aug;16(18):1545-1548.
doi: 10.2217/nnm-2021-0114.
Epub 2021 Jun 29.
Authors
Yinghan Chan
1
,
Meenu Mehta
2
3
,
Keshav Raj Paudel
3
4
,
Thiagarajan Madheswaran
5
,
Jithendra Panneerselvam
5
,
Gaurav Gupta
6
,
Qian Peter Su
7
,
Philip Michael Hansbro
3
4
,
Ronan MacLoughlin
8
9
10
,
Kamal Dua
2
3
,
Dinesh Kumar Chellappan
11
Affiliations
1
School of Pharmacy, International Medical University (IMU), Bukit Jalil, Kuala Lumpur, 57000, Malaysia.
2
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia.
3
Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia.
4
School of Life Sciences, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
5
Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia.
6
School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, 302017, India.
7
School of Biomedical Engineering, Faculty of Engineering & Information Technology, University of Technology Sydney, Sydney, NSW, 2007, Australia.
8
Aerogen, IDA Business Park, Dangan, Galway, H91 HE94, Ireland.
9
School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, D02 YN77, Ireland.
10
School of Pharmacy & Pharmaceutical Sciences, Trinity College, Dublin, D02 PN40, Ireland.
11
Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia.
PMID:
34184917
DOI:
10.2217/nnm-2021-0114
No abstract available
Keywords:
drug delivery; inflammation; liquid crystalline nanoparticles; lung disease.
Publication types
Editorial
MeSH terms
Humans
Liquid Crystals*
Lung Diseases* / drug therapy
Nanoparticles*